NO310032B1 - Fremgangsmåte for fremstilling av fibroblast- vekstfaktorreseptor-blokkerende forbindelse, anvendelse av et löselig peptid, isolert nukleinsyre, fremgangsmåte for fremstilling av antistoff, anvendelse av et fibroblastvekstfaktorreseptor, samt tra - Google Patents

Fremgangsmåte for fremstilling av fibroblast- vekstfaktorreseptor-blokkerende forbindelse, anvendelse av et löselig peptid, isolert nukleinsyre, fremgangsmåte for fremstilling av antistoff, anvendelse av et fibroblastvekstfaktorreseptor, samt tra Download PDF

Info

Publication number
NO310032B1
NO310032B1 NO920060A NO920060A NO310032B1 NO 310032 B1 NO310032 B1 NO 310032B1 NO 920060 A NO920060 A NO 920060A NO 920060 A NO920060 A NO 920060A NO 310032 B1 NO310032 B1 NO 310032B1
Authority
NO
Norway
Prior art keywords
growth factor
fgf
fibroblast growth
receptor
factor receptor
Prior art date
Application number
NO920060A
Other languages
English (en)
Norwegian (no)
Other versions
NO920060D0 (no
NO920060L (no
Inventor
Lewis T Williams
Daniel E Johnson
Pauline L Lee
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of NO920060D0 publication Critical patent/NO920060D0/no
Publication of NO920060L publication Critical patent/NO920060L/no
Publication of NO310032B1 publication Critical patent/NO310032B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
NO920060A 1989-07-06 1992-01-03 Fremgangsmåte for fremstilling av fibroblast- vekstfaktorreseptor-blokkerende forbindelse, anvendelse av et löselig peptid, isolert nukleinsyre, fremgangsmåte for fremstilling av antistoff, anvendelse av et fibroblastvekstfaktorreseptor, samt tra NO310032B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37700389A 1989-07-06 1989-07-06
PCT/US1990/003830 WO1991000916A2 (fr) 1989-07-06 1990-07-06 Recepteurs pour facteurs de croissance de fibroblastes

Publications (3)

Publication Number Publication Date
NO920060D0 NO920060D0 (no) 1992-01-03
NO920060L NO920060L (no) 1992-03-02
NO310032B1 true NO310032B1 (no) 2001-05-07

Family

ID=23487374

Family Applications (1)

Application Number Title Priority Date Filing Date
NO920060A NO310032B1 (no) 1989-07-06 1992-01-03 Fremgangsmåte for fremstilling av fibroblast- vekstfaktorreseptor-blokkerende forbindelse, anvendelse av et löselig peptid, isolert nukleinsyre, fremgangsmåte for fremstilling av antistoff, anvendelse av et fibroblastvekstfaktorreseptor, samt tra

Country Status (15)

Country Link
US (4) US6384191B1 (fr)
EP (1) EP0481000B1 (fr)
JP (1) JP3039802B2 (fr)
KR (1) KR100235266B1 (fr)
AT (1) ATE179862T1 (fr)
AU (1) AU638734B2 (fr)
CA (1) CA2063431C (fr)
DE (1) DE69033109T2 (fr)
DK (1) DK0481000T3 (fr)
ES (1) ES2133271T3 (fr)
FI (1) FI920027A7 (fr)
HU (1) HU215581B (fr)
NO (1) NO310032B1 (fr)
SG (1) SG72657A1 (fr)
WO (1) WO1991000916A2 (fr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9001466D0 (en) * 1990-01-23 1990-03-21 Erba Carlo Spa Extracellular form of the human fibroblast growth factor receptor
HU215581B (hu) * 1989-07-06 1999-01-28 Regents Of The University Of California Eljárás fibroblaszt növekedési faktor receptorok előállítására és terápiás alkalmazására
JP2552942B2 (ja) * 1990-06-01 1996-11-13 三井東圧化学株式会社 ヒトｂーＦＧＦ受容体遺伝子
EP0538404B1 (fr) * 1990-07-06 2003-06-18 Rhone-Poulenc Rorer International (Holdings) Inc. Recepteurs de facteur de croissance fibroblastique
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
IL100219A0 (en) * 1991-12-02 1992-09-06 Yeda Res & Dev Variable region within fibroblast growth factor receptors that confers ligand specificity
WO1994000599A2 (fr) * 1992-06-18 1994-01-06 Whittier Institute For Diabetes And Endocrinology Procede de detection des maladies neoplasiques
AU687727B2 (en) * 1992-10-28 1998-03-05 Genentech Inc. Vascular endothelial cell growth factor antagonists
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US6214795B1 (en) 1996-11-12 2001-04-10 Praecis Pharmaceuticals, Inc. Peptide compounds useful for modulating FGF receptor activity
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
WO1999055861A2 (fr) * 1998-04-28 1999-11-04 Eisai Co., Ltd. Compositions de muteine du facteur de croissance de fibroblastes et procedes d'utilisation associes
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US20020192719A1 (en) * 1998-09-30 2002-12-19 Caliper Technologies Corp. Homogeneous assay methods
US6656728B1 (en) 1999-02-08 2003-12-02 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
CZ20014083A3 (cs) * 1999-05-14 2002-08-14 Imclone Systems Incorporated Léčivo pro indikaci růstu refrakterních nádorů
WO2002011677A2 (fr) * 2000-08-09 2002-02-14 Imclone Systems Incorporated Traitement de maladies hyperproliferatives au moyen d'antagonistes du recepteur de facteur de croissance epidermique
US6812221B2 (en) 2000-11-21 2004-11-02 The Texas A&M University System FGF-affinity chromatography
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
CA2450793A1 (fr) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Anticorps bloquant l'activation d'un recepteur a activite proteine tyrosine kinase, procedes de criblage et utilisations associes
AU2003212293A1 (en) * 2002-02-28 2003-09-09 Switch Biotech Ag Use of a fibroblast growth factor-binding protein for the treatment and diagnosis of diabetic wound healing problems
EP1340507B1 (fr) * 2002-02-28 2004-09-22 Switch Biotech Aktiengesellschaft Utilisation de la protéine liant au facteur de croissance de fibroblastes pour le traitement et le diagnostic de la cicatrisation diabétique
JP2007524566A (ja) 2002-12-20 2007-08-30 エンカム ファーマシューティカルズ アクティーゼルスカブ レセプターとリガンドの間の相互作用の調節の方法
EP1622941A2 (fr) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Procede de production d'un anticorps contre le recepteur du facteur de croissance epidermique
EP1697420A2 (fr) * 2003-12-19 2006-09-06 Five Prime Therapeutics, Inc. Utilisation des recepteurs 1, 2, 3 et 4 du facteur de croissance des fibroblastes comme cibles pour une intervention therapeutique
CA2560305C (fr) * 2004-03-19 2016-07-05 Imclone Systems Incorporated Anticorps du recepteur du facteur de croissance anti-epidermique humain
US20060234347A1 (en) * 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
EP2083081A1 (fr) 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Compositions et procédés pour traiter une maladie avec des protéines de fusion FGFR
WO2007109733A2 (fr) 2006-03-21 2007-09-27 The Johns Hopkins University Marqueurs de diagnostic et de pronostic et strategies de traitement de la sclerose en plaques
MX2009005466A (es) 2006-11-22 2009-08-17 Adnexus A Bristol Myers Sqibb Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas, incluyendo receptor de factor de crecimiento tipo insulina-i.
AR063975A1 (es) 2006-11-28 2009-03-04 Centelion Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada
AU2009213141A1 (en) 2008-02-14 2009-08-20 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind EGFR
WO2009142773A2 (fr) 2008-05-22 2009-11-26 Bristol-Myers Squibb Company Protéines à domaines d’échafaudage à base de fibronectine multivalente
US8034770B2 (en) 2008-06-04 2011-10-11 Amgen Inc. FGF21 polypeptides comprising two or more mutations
EP2313435A4 (fr) * 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc Protéines se liant au récepteur 3 du facteur de croissance des fibroblastes (fgfr3)
EP2318529B1 (fr) 2008-08-04 2017-10-18 Five Prime Therapeutics, Inc. Mutéines de la région acide du domaine extracellulaire de FGFR.
CA2739615C (fr) 2008-10-10 2017-12-05 Amgen Inc. Mutants fgf21 et leurs utilisations
HUE035700T2 (en) 2008-11-07 2018-05-28 Galaxy Biotech Llc Monoclonal antibodies to Fibroblast Growth Factor receptor 2
MA33208B1 (fr) 2009-03-25 2012-04-02 Genentech Inc Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
WO2010129600A2 (fr) 2009-05-05 2010-11-11 Amgen Inc. Mutants de fgf21 et leurs utilisations
WO2010129503A1 (fr) * 2009-05-05 2010-11-11 Amgen Inc. Mutants de fgf21 et leurs utilisations
MX2011013903A (es) * 2009-06-17 2012-05-08 Amgen Inc Polipeptidos quimericos y usos de los mismos.
US8445445B2 (en) 2009-09-15 2013-05-21 Five Prime Therapeutics, Inc. Method of promoting hair growth using FGFR4 extracellular domains
LT2498799T (lt) 2009-11-13 2016-11-10 Five Prime Therapeutics, Inc. Fgfr1 ekstraląstelinio domeno baltymų panaudojimas gydymui vėžio su nuo ligando priklausančiomis, aktyvuojančiomis fgfr2 mutacijomis
EP2679234A3 (fr) * 2009-12-02 2014-04-23 Amgen Inc. Protéines de liaison qui se lient au FGFR1C humain, au beta-klotho humain et aux deux ensemble
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
WO2011084711A2 (fr) 2009-12-17 2011-07-14 Five Prime Therapeutics, Inc. Procédés favorisant la pousse des cheveux à l'aide des domaines extracellulaires de fgfr3
CA2796055A1 (fr) 2010-04-15 2011-10-20 Amgen Inc. Proteines de liaison au recepteur de fgf humain et a ?-klotho
US8435525B1 (en) 2010-04-16 2013-05-07 Andrew B. Bush FGF modulation of in vivo antibody production and humoral immunity
US9226960B2 (en) 2010-04-16 2016-01-05 Andrew B. Bush FGF modulation of in vivo antibody production and humoral immunity
RU2012153241A (ru) 2010-05-11 2014-06-20 Авео Фармасьютикалз, Инк. Антитела к fgfr2
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
KR101910779B1 (ko) 2010-11-15 2018-10-22 파이브 프라임 테라퓨틱스, 인크. Ｆｇｆｒ１ 세포밖 도메인 조합치료
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
CN107823630A (zh) 2011-11-14 2018-03-23 戊瑞治疗有限公司 治疗癌症的方法
KR102516152B1 (ko) 2013-08-01 2023-03-31 파이브 프라임 테라퓨틱스, 인크. 비푸코실화된 항-ｆｇｆｒ２ｉｉｉｂ 항체
US10373702B2 (en) * 2014-03-27 2019-08-06 Massachusetts Institute Of Technology Water-soluble trans-membrane proteins and methods for the preparation and use thereof
EP3197474B1 (fr) 2014-09-26 2023-06-07 Rajendra Sahai Bhatnagar Inhibiteurs de l'activité de nf-kappa-b pour le traitement de certaines maladies et de certains troubles
CN115925878A (zh) 2015-06-05 2023-04-07 艾比欧公司 用于治疗纤维化的内皮抑素片段和变体
MX2018006181A (es) 2015-11-23 2018-09-24 Five Prime Therapeutics Inc Inhibidores de fgfr2 solos o en combinacion con agentes que estimulan el sistema inmunitario en el tratamiento contra el cancer.
PT3624837T (pt) 2017-05-16 2025-10-01 Five Prime Therapeutics Inc Anticorpos anti-fgfr2 em combinação com agentes quimioterapêuticos no tratamento do cancro
CA3189470A1 (fr) 2020-08-21 2022-02-24 Yves SABBAGH Anticorps anti-fgfr3 et methodes d'utilisation
US12129302B2 (en) 2021-08-25 2024-10-29 Ibio, Inc. Anti-CD-25 antibody

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394443A (en) * 1980-12-18 1983-07-19 Yale University Method for cloning genes
US4785079A (en) * 1984-11-09 1988-11-15 The Salk Institute For Biological Studies Isolation of fibroblast growth factor
US4668476A (en) * 1984-03-23 1987-05-26 Applied Biosystems, Inc. Automated polypeptide synthesis apparatus
US4761371A (en) 1985-02-12 1988-08-02 Genentech, Inc. Insulin receptor
US4859609A (en) * 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
US5057417A (en) * 1987-06-12 1991-10-15 Genentech, Inc. Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein
US4968607A (en) * 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5081228A (en) * 1988-02-25 1992-01-14 Immunex Corporation Interleukin-1 receptors
SE8804164A0 (sv) * 1988-11-17 1990-05-18 Per Prisell Farmaceutisk beredning
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
HU215581B (hu) * 1989-07-06 1999-01-28 Regents Of The University Of California Eljárás fibroblaszt növekedési faktor receptorok előállítására és terápiás alkalmazására
US5229501A (en) * 1991-01-11 1993-07-20 Chiron Corporation Expression and use of human fibroblast growth factor receptor
US6022741A (en) * 1997-03-13 2000-02-08 University Of North Carolina At Chapel Hill Regulatory genetic DNA that regulates the Class II transactivator (CIITA)

Also Published As

Publication number Publication date
EP0481000B1 (fr) 1999-05-12
CA2063431C (fr) 2002-10-29
AU638734B2 (en) 1993-07-08
HUT61052A (en) 1992-11-30
SG72657A1 (en) 2000-05-23
HU906195D0 (en) 1992-06-29
NO920060D0 (no) 1992-01-03
FI920027A0 (fi) 1992-01-03
JP3039802B2 (ja) 2000-05-08
WO1991000916A3 (fr) 1991-10-17
AU6077990A (en) 1991-02-06
DE69033109T2 (de) 1999-11-18
NO920060L (no) 1992-03-02
EP0481000A1 (fr) 1992-04-22
WO1991000916A2 (fr) 1991-01-24
EP0481000A4 (en) 1992-10-21
US6355440B1 (en) 2002-03-12
DK0481000T3 (da) 1999-11-15
JPH04506604A (ja) 1992-11-19
DE69033109D1 (de) 1999-06-17
ES2133271T3 (es) 1999-09-16
ATE179862T1 (de) 1999-05-15
US5707632A (en) 1998-01-13
FI920027A7 (fi) 1992-01-03
US6384191B1 (en) 2002-05-07
HU215581B (hu) 1999-01-28
CA2063431A1 (fr) 1991-01-07
KR100235266B1 (en) 1999-12-15
US6350593B1 (en) 2002-02-26

Similar Documents

Publication Publication Date Title
NO310032B1 (no) Fremgangsmåte for fremstilling av fibroblast- vekstfaktorreseptor-blokkerende forbindelse, anvendelse av et löselig peptid, isolert nukleinsyre, fremgangsmåte for fremstilling av antistoff, anvendelse av et fibroblastvekstfaktorreseptor, samt tra
US5686572A (en) Domains of extracellular region of human platelet derived growth factor receptor polypeptides
EP0814827B1 (fr) Facteur de croissance-b des cellules endotheliales vasculaires
EP0586607B1 (fr) HEREGULINES (HRGs), PROTEINES DE LIAISON DE P185?erb2
US5820859A (en) Method of targeting a therapeutic agent to cells expressing the erb B-3 receptor
US5367060A (en) Structure, production and use of heregulin
EP0577752B1 (fr) Receptor humain pf4a et leur utilisation
EP0538404B1 (fr) Recepteurs de facteur de croissance fibroblastique
US5863888A (en) Human Bek Fibroblast growth factor receptor
US6475782B1 (en) Human platelet-derived growth factor receptor
US20030211991A1 (en) Human sez6 nucleic acids and polypeptides
US6696259B1 (en) Assays using glial cell line-derived neurotrophic factor receptors
WO2001083552A2 (fr) Acides nucleiques et polypeptides sez6 humains
EP1007072A1 (fr) Recepteurs du facteur neurotrophique derive de lignes de cellules gliales

Legal Events

Date Code Title Description
MK1K Patent expired